Written By: Samiksha Jadhav BPharm Reviewed By: Pharmacally Editorial Team Regeneron Pharmaceuticals has reported positive topline results from a Phase 3 clinical trial evaluating olatorepatide, a dual GLP-1/GIP receptor agonist being developed for adults with obesity or overweight
Can I freeze MIC B12 to extend shelf life
Medication creates an opportunity, but habits often determine long-term success
Weight-loss drug explosion PwC described the GLP-1 market as poised for explosive growth. Its GLP-1 Trends & Impact Survey found that more than 8% of Americans already are taking GLP-1 medications, and nearly 35% are interested in these drugs for weight loss
The reviewer JX declared a shared parent affiliation with the authors LKZ, FX, XZ, LDZ and MW to the handling editor at the time of review
Yet this effect is more pronounced and common with Acetyl-L-Carnitine